Timber Pharmaceuticals, Inc. (TMBR)

NYSEAMERICAN: TMBR · IEX Real-Time Price · USD
0.102
0.000 (-0.39%)
At close: Aug 8, 2022 4:00 PM
0.112
+0.010 (9.668%)
Pre-market: Aug 9, 2022 5:49 AM EDT
-0.39%
Market Cap 6.53M
Revenue (ttm) 928,975
Net Income (ttm) -11.93M
Shares Out 63.75M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 24,147,350
Open 0.106
Previous Close 0.103
Day's Range 0.101 - 0.109
52-Week Range 0.090 - 1.120
Beta -0.17
Analysts Buy
Price Target 1.53 (+1,394.1%)
Earnings Date Aug 8, 2022

About TMBR

Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angio... [Read more...]

Industry Biotechnology
Founded 2019
Employees 5
Stock Exchange NYSEAMERICAN
Ticker Symbol TMBR
Full Company Profile

Financial Performance

In 2021, TMBR's revenue was $886,532, an increase of 95.35% compared to the previous year's $453,810. Losses were -$10.64 million, -29.62% less than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for TMBR stock is "Buy." The 12-month stock price forecast is 1.53, which is an increase of 1,394.14% from the latest price.

Price Target
$1.53
(1,394.14% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering

Basking Ridge, NJ, Aug. 08, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire --  Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the deve...

Timber Pharmaceuticals Announces Pricing of $8.0 Million Public Offering

Basking Ridge, NJ, Aug. 04, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the devel...

Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Conge...

Pivotal Trial Expected to Enroll More Than 140 Patients With Moderate to Severe Congenital Ichthyosis at Leading Research Centers in the U.S., Canada, Italy, France, and Germany

Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Icht...

- Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial -

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results

Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30th, 2022

Best Penny Stocks to Buy Under $1? 3 to Watch as April Ends

Are these under $1 penny stocks on your watchlist? The post Best Penny Stocks to Buy Under $1?

Other symbols: IMPPITP

Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital I...

Company expects to launch pivotal Phase 3 ASCEND clinical trial to evaluate TMB-001 within the next 60 days

Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial Results

Company Plans to Initiate Phase 3 Study for TMB-001 in Q2 2022

Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting

Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001 regardless of subtype

Timber Pharmaceuticals: Invitation to the Q1 Virtual Investor Summit

Basking Ridge, New Jersey--(Newsfile Corp. - February 28, 2022) - Timber Pharmaceuticals (NYSE American: TMBR) today announced that John Koconis, Chairman and CEO will be attending the Q1 Virtual Invest...

Timber Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenita...

- Full data from Phase 2b CONTROL study presented at 2022 Winter Clinical Dermatology Conference -

Timber Pharmaceuticals to Present at H.C. Wainwright BioConnect Conference

Virtual Conference on January 10-13, 2022

Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Con...

Call to be held on Monday, November 22nd at 10:00am ET

Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2021 Financial Results

Positive Top Line Phase 2b Study Data for Lead Asset TMB-001 and Capital Rais e of $17.25 Million   Announced Subsequent to Quarter End

Timber Pharmaceuticals Announces Closing of Exercise of Underwriter's Option to Purchase Additional Common Stock

Underwritten Public Offering Resulted in Total Gross Proceeds of $17.25 Million

Timber Pharmaceuticals Announces Closing of $15 Million Public Offering

Basking Ridge, NJ, Nov. 05, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the devel...

Timber Pharmaceuticals Announces Pricing of $15 Million Public Offering

Basking Ridge, NJ, Nov. 03, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the develo...

Timber Pharmaceuticals Announces Proposed Public Offering

Basking Ridge, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the develo...

Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate t...

Basking Ridge, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the devel...

Timber Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BASKING RIDGE, NJ, Sept. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the develo...

Timber Pharmaceuticals Announces Last Patient Last Visit in Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to ...

- Topline results expected to be announced in the fourth quarter of 2021 -

7 Hottest Penny Stocks to Pick Up Now

Penny stocks from companies that have reasonable business fundamentals. Stocks that can possibly provide multi-fold returns.

Other symbols: GNUSOBSVREISNDL

Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2021 Financial Results

BASKING RIDGE, NJ, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the develo...

7 Reddit Penny Stocks to Watch for Big Upside Ahead

If we've learned anything from the Reddit in January, it's not to underestimate them. These 7 Reddit penny stocks have good upsides.

Other symbols: CTXRNOKRIGSNDL

Timber Pharmaceuticals Announces Adjournment of Annual Meeting

Basking Ridge, NJ, June 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the develo...